Printer Friendly

Asthma treatment in children: A pragmatic approach.

The South African Childhood Asthma Working Group (SACAWG), a subcommittee of the Allergy Society of South Africa (ALLSA), first published its guideline for the management of chronic asthma in children and adolescents in 1992, followed by revisions in 1994, [1] 2000 [2] and 2009. [3] In the interim, there have been a number of key changes in the diagnostic criteria (particularly in young children, assessment of asthma control, management principles, new drugs and new drug-delivery devices).

Pharmacotherapy is the cornerstone of asthma management. Selection of medication and delivery devices has to meet the patients' needs and characteristics. Periodic assessment of asthma control and review of management are critical to gain control of the disease and limit medication side-effects. [delta] Methods

SACAWG reconvened in January 2017 with 6 task groups, each headed by a leader (Appendix A), constituting the editorial committee on assessment of asthma epidemiology, diagnosis, control, treatments, novel treatments and self-management plans. The asthma medication task groups were charged with the responsibility of reviewing the available scientific literature and assigning evidence levels according to the methodology used in current guideline documents. PubMed and Google Scholar searches were done to review the current level of evidence since the publication of the previous guideline. [3] The level of evidence and key recommendations were graded (Appendix B) according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. After completion of each sub-section, it was sent to the entire working group for review, comment and revision. Any disagreements or inconsistencies were dealt with via round robin, with a majority recommendation based on the evidence if there was disagreement.

Assessment of severity to initiate therapy

The method of assessment conforms to international assessment criteria. The assessment of severity is used to assign a child to a particular treatment group as a starting point. This assessment refers to a child's symptoms and lung function (peak expiratory flow (PEF) or forced expiratory flow in 1 second ([FEV.sub.1])) between acute episodes if they are not receiving long-term therapy (Table 1). Severity can also be measured once asthma control is achieved by the step of care (i.e. various medications) required to maintain control. One or more features must be present to assign a severity grading to the most severe grade in which any feature occurs.

Principles of medication

When selecting medication for an asthmatic patient, the following principles apply: regular anti-inflammatory medication is indicated for persistent asthma, but inhaled therapy is preferable, especially inhaled bronchodilators and inhaled steroids.

Drugs are classified as:

* Relievers (bronchodilators) for acute relief from symptoms, including inhaled short-acting [beta.sub.2]-agonists (SABAs) (evidence level I) and anticholinergics. Short-acting xanthines are not recommended in the maintenance treatment of asthma. Anticholinergics are less potent, have a slower onset of action (30-60 minutes) and can be used during exacerbations.

* Controllers (anti-inflammatory drugs) for long-term control may modify airway inflammation that is characteristic of asthma. Inhaled corticosteroids (ICSs) are the most effective controller therapy for asthma (evidence level I). Leukotriene receptor antagonists (LTRAs) are anti-inflammatories that exert their effects via different pathways than ICSs. Long-acting [beta.sub.2]-agonists (LABAs) have weak anti-inflammatory effects. Slow-release theophyllines also have weak anti-inflammatory effects at lower doses than those required for bronchodilation.

A number of different ICS preparations are available in South Africa (SA) (Tables 2 and 3). ICSs are usually administered twice daily, but budesonide and ciclesonide (registered only for children >12 years old) are approved for once-daily use in children with mild asthma. Most children >5 years of age are controlled on low daily doses of ICSs (100-200 [micro]g budesonide or equivalent). Wheezing caused by viral infections is very common in children <2 years of age and often resolves spontaneously or remits with increasing age. ICSs should only be used if symptoms are particularly troublesome, and if there is a need for admission and oxygen therapy, with a clear response to treatment. Most importantly, the administration of ICSs should be discontinued if there is no response or a poor response. LABAs should only be used in combination with an ICS. LABAs are primarily indicated as add-on therapy in children >5 years of age, whose asthma is not controlled by moderate doses of ICSs (evidence level II) (Table 4).

LTRAs have a rapid onset of action (1-3 hours) and are taken once a day. They are available in 5 mg tablets, 4 mg chewable tablets and 4 mg oral granule formulations. Because of easy administration (compared with inhaler devices) and once-daily dosing, patients are often adherent to LTRAs only. It should be noted and explained to parents that LTRAs are not the preferred first-line treatment for asthma. LTRAs have been shown to be inferior to ICSs with regard to symptom improvement, exacerbation decrease and hospitalisation frequency in the treatment of asthma in the preschool child. This medication may be used as add-on therapy in children >5 years of age, whose asthma is insufficiently controlled by low doses of ICSs (evidence level II), or as alternative first-line therapy to ICSs for episodic or mild persistent asthma in children <5 years old (evidence level II).

Theophylline may be used as add-on therapy in more severe asthma that is not controlled with ICSs in children >12 years of age and in adults (evidence level IV), but safety concerns preclude its recommendation.

Oral corticosteroids should only be used for acute asthma exacerbations, preferably only in hospitalised patients and for a maximum of 3 days at 0.5-1 mg/kg/dose of prednisone given once daily. For children <5 years old, these are only recommended in exacerbations that require hospitalisation.

Routes of administration

Inhaled medications

Inhaled therapy is the cornerstone of asthma treatment for all children. Most children can be taught to use inhaled therapy effectively. Different age groups require different inhaler devices together with a pressurised metered-dose inhaler (pMDI) with or without a holding chamber (spacer). The alternative is a dry powder metered-dose inhaler (DPI) (Box 1). Considerations when choosing an inhaler device include the efficacy of drug delivery, cost, safety, ease of use, convenience and efficacy in a specific age group. [5] A pMDI with holding chamber (spacer) is preferable to nebulised therapy owing to convenience, more effective lung deposition, fewer side-effects and lower cost. [6-8] The technique for each device type varies, has to be correct for optimal drug delivery and should be checked at each visit (Box 2).

Valved holding chamber (spacer)

Valved holding chambers allow inhalation at a normal respiratory rhythm even without synchronising actuation and inhalation, thus increasing inhalation efficiency. Spacers also retain large drug particles that would otherwise be deposited in the oropharynx.
Box 1. Choice of inhaler device for children

Age group, years   Preferred device

<4                 pMDI and spacer with face mask
4-6                pMDI and spacer with mouthpiece
>6                 Dry powder inhaler, or pMDI with spacer
                   and mouthpiece or breath-actuated pMDI

pMDI = pressurised metered-dose inhaler.

Box 2. Correct use of pressurised metered-dose inhaler and holding
chamber (spacer)

Assemble spacer, remove mouthpiece cover from the pMDI, and attach

Shake canister vigorously for 5 s, then hold assembled
canister-spacer/ chamber in a horizontal position

Breathe out normally

Place mouthpiece of spacer/chamber into mouth and close lips around
mouthpiece *

At the start of the next inhalation, actuate the pMDI

Keep inhaling deeply and slowly through your mouth. If you hear a
whistling sound from the chamber, slow down the rate of inhalation

Hold your breath for 5-10 s. Then breathe out slowly and
gently ([dagger])

Wait 15-30 s before you give the second puff, if required. Shake
the inhaler again before the second puff

If the inhaler is a steroid medicine, rinse out your mouth, gargle,
and spit out the water

Remove the pMDI from spacer/chamber and replace the mouthpiece

pMDI = pressurised metered-dose inhaler.

* If the spacer has a facemask, hold the latter snugly over the
child's mouth and nose.

([dagger]) In a young child who cannot follow instructions, press
the pMDI at the start of a slow breath in and keep mask firmly in
place for 5-6 breaths.

This reduces oropharyngeal side-effects, systemic absorption and bio-availability of inhaled drug. It is especially important for ICSs with first-pass metabolism, such as beclomethasone and budesonide.


A pMDI with a spacer is as effective as, or more effective than, nebulised treatment for acute, severe asthma exacerbation. [8,9] Nebulisers have imprecise dosing, are expensive and waste large amounts of drug into the surrounding air. For home use, nebulisers are discouraged; they should be restricted to cases where oxygen administration is necessary and available (evidence level I).

Dry powder inhaler

A DPI is a breath-actuated device containing micronised drug particles with a mass median aerodynamic diameter of <5 [micro]m. [10,11] DPI devices eliminate the requirement for propellants, as well as for co-ordination between inhalation and device actuation. The disadvantage of DPIs is the high inspiratory flow rates (30-120 L/ min) that are required to aerosolise the drug. [11,12] In one study, the age at which most children who were inexperienced in the use of a DPI could generate a peak inspiratory flow rate of [greater than or equal to] 30 L/min was 4 years, and the age at which most children could generate a peak inspiratory flow rate of [greater than or equal to] 60 L/min was 9 years. [12] Furthermore, the rapid inhalation required to ensure optimal lung deposition might be confusing for children who use both an MDI and a DPI. It should be noted that equivalent doses for these devices also differ.

Treatment options

Before stepping up of treatment, symptom control, steroid side-effects and comorbid conditions (e.g. allergic rhinitis) must be assessed. Ensure adequate patient education (e.g. inhaler skills, adherence and written asthma action plan). Assess environmental exposure to allergens and irritants, especially tobacco smoke. Consider the possibility of an alternative diagnosis, poor adherence to treatment or incorrect inhaler technique. Do not step up treatment unless the abovementioned problems have been addressed (Tables 5 and 6).

Step 1: Short-acting [beta.sub.2]-agonist as needed

In the case of mild symptoms (not requiring oral corticosteroids and hospital admission with supplemental oxygen), a SABA with a dedicated spacer device, facemask and an adequate technique are indicated. This treatment is reserved for infrequent symptoms and will not prevent future exacerbations.

ICSs should be considered for patients with any of the following asthma-related features:[14-16]

* an asthma attack in the past 2 years, requiring the use of bronchodilators and systemic steroids

* using inhaled SABAs [greater than or equal to] 3 times a week

* symptomatic [greater than or equal to] 3 times a week

* nocturnal waking [greater than or equal to] 1 times a week.

Step 2: Low-dose controller medication and as-needed reliever medication

In all children the preferred option is regular low-dose ICSs, which are the most effective preventer drugs for adolescents and older children for achieving overall treatment goals (evidence level I). [13-15] Treatment with low-dose ICSs reduces asthma symptoms, improves lung function and quality of life, and reduces the risk of exacerbations, asthma-related hospitalisations and death (evidence level I). [13,17,18]

Alternative options

In young children with recurrent viral-induced wheezing, regular LTRAs improve some asthma outcomes compared with placebo, but do not reduce the frequency of hospitalisation, courses of prednisone, or number of symptom-free days (evidence level I). As an alternative, LTRAs have some beneficial clinical effects and may be used as initial controller treatment in children unable or unwilling to use ICSs, for patients who experience intolerable side-effects from ICSs or for those with concomitant allergic rhinitis (evidence level II). [19-23]

Intermittent inhaled corticosteroids

For patients with purely seasonal allergic asthma, with no inter-current asthma symptoms, ICSs should be started immediately when symptoms commence and continued for 4 weeks after the relevant pollen season ends (evidence level IV). Daily ICSs are superior to intermittent ICSs in several indicators of lung function, airway inflammation, asthma control and reliever use. The strength of the evidence means that, currently, equivalence cannot be assumed between the two options and therefore it is recommended to use daily ICSs (evidence level I). [24]

Step 3: Add an additional controller and as-needed reliever medication

A poor response to low-dose ICSs should be escalated to medium-dose ICSs with as-needed SABAs as the preferred treatment option. In children <6 years of age an alternative treatment is medium-dose ICSs or the addition of an LTRA. As an alternative choice, a low-dose ICS/LABA combination with an as-needed SABA can be administered to children >6 years old. To date, evidence shows that the outcomes of these two treatments are similar. [25,26] However, meta-analyses demonstrated a trend towards increased risk of exacerbations requiring rescue therapy and hospitalisation with ICS/ LABA treatment in children <12 years compared with medium-dose ICSs (evidence level I). [24-26] Based on this, it is currently recommended to escalate therapy to medium-dose ICSs as the preferred choice in this age group.

For children [greater than or equal to] 12 years of age, the first choice is adding a LABA to a low-dose ICS. There are two strategies for doing this. The traditional approach of combination ICS/LABA therapy with as-needed SABA reliever therapy is well proven to improve asthma control rather than ICSs alone (evidence level I). [27] The more recent approach of ICS/formoterol maintenance and reliever therapy (or single-inhaler therapy) may, however, be preferable to traditional fixed-dose ICS/ LABA therapy. Studies comparing the two demonstrate a reduced daily dose of ICS and a reduced exacerbation rate requiring oral steroids or hospitalisation in the former group (evidence level I). [27-31] Of particular importance is that in any age group LABAs should never be used alone and should only be used in combination with an ICS.
Box 3. Options for stepping-down treatment in well-controlled asthma *

Current   Current medication   Options for stepping down    Evidence
  step    and dose                                          level

Step 4    Moderate- to high-   Continue ICS/LABA with       II
          dose ICS/LABA        50% reduction in ICS

                               Discontinuation of LABA is   I
                               more likely to lead to
                               deterioration [40]

          Medium-dose ICS/     Reduce maintenance ICS/      IV

          formoterol as        formoterol to low dose,
          maintenance and      continue as needed with
          reliever             low/dose ICS/formoterol

          High-dose ICS and    Reduce ICS dose by           II
          second controller    50% and continue
                               controller [41]

Step 3    Low-dose ICS/LABA    Reduce ICS/LABA to           IV
                               once-daily dosing

          Low-dose ICS/        Discontinuation of LABA is   I
          formoterol as        more likely to lead to
          maintenance and      deterioration [40]

                               Reduce maintenance ICS/      III
                               formoterol dose to once
                               daily and continue as
                               needed with low/dose ICS/
                               formoterol reliever

Step 2    Moderate- or         Reduce ICS dose by 50%       I
          high-dose ICS        [41]

          Low-dose ICS         Once-daily dosing            I
                               (budesonide, ciclesonide,

          Low-dose ICS         Consider stopping            IV
          or LTRA              controller treatment if no
                               symptoms for 6-12 months
                               and no risk factors

ICS = inhaled corticosteroid; LABA = long-acting [beta.sub.2]-agonist;
LTRA = leukotriene receptor antagonist. * Adapted from South
African Childhood Asthma Working Group. [1]

The addition of slow-release theophylline to a low-dose ICS has a similar effect as an increase from low- to medium/high-dose ICS (evidence level II). [32]

Step 4: Two or more controllers and as-needed reliever medication

Other options in this group are switching to high-dose ICSs and adding a second controller, or adding a third controller to a failing medium-dose ICS/LABA regimen. Tiotropium administered by means of a mist inhaler has been demonstrated to improve asthma control in patients who receive medium-dose ICS/LABA therapy and was non-inferior to adding salmeterol to medium/high-dose steroid monotherapy in severe asthma (evidence level I). [33] Similarly, the addition of an LTRA [34-37] (evidence level II) or slow-release theophylline [70] (evidence level II) is efficacious in improving asthma control in severe asthmatics.

Of note is that ICSs have a relatively flat dose-response curve. The main benefits appear to be gained from the use of low- to medium-dose steroids. An increase to high-dose steroids confers little advantage, at the expense of greater side-effects (evidence level I). [38,39] Hence, it is generally preferable to add a second or third controller to a failing regimen than increasing the steroid burden.

Step 5: Refer

All children with severe asthma who fail appropriate therapy should be referred to a paediatrician, paediatric allergologist or paediatric pulmonologist for further management, also to confirm the diagnosis and exclude aggravating comorbidities.

Stepping-down treatment

Stepping-down treatment should be considered once good asthma control has been achieved and maintained for 3 months and lung function has reached a plateau (evidence level IV). Any step-down treatment depends on patient characteristics, as only a few step-down studies have been performed in children. Approach each step as a therapeutic trial. Provide clear instructions and an asthma action plan. Monitor symptoms and/or PEF and schedule a follow-up visit. Stepping down ICS doses by 25-50% at 3-month intervals is feasible and safe for most patients (evidence level I). When stepping down to once-daily dosing, it should preferably be a morning dose. Box 3 summarises step-down strategies for different controller treatments.


To ensure a good response from treatment and adherence, the type of medication, device and checking of technique are critical. Stepping up of therapy should be done only after ensuring good adherence and technique. Once therapeutic response is achieved, medication has to be stepped down to improve ease of medication use and avoid unnecessary side-effects.

Acknowledgements. We would like to acknowledge the hard work and contribution of the South African Childhood Asthma Working Group (SACAWG) members. We also acknowledge the huge contribution of the late Prof. Cas Motala, who was convener of the past three SACAWG guideline groups. The current guideline was sent to external reviewers and for comment from the Department of Health (Drs Gavin Steele and Jane Ridden) and members of the Allergy Society of South Africa. Author contributions. RM: review, write-up and manuscript writing and editing; FEK, AJ, SK, JM, ASP, DR, PdW EWZ, TCG, AV: conceptualisation, review, write-up and manuscript editing; and HZ, ML, RJG, AIM: write-up and manuscript editing.

Funding. SACAWG conducted a workshop that received an unconditional educational grant from the Allergy Society of South Africa--funded by Novartis.

Conflicts of interest. RM: advisory board for AstraZeneca and AbbVie, and speaker for Cipla, AstraZeneca, AbbVie and Norvartis. FEK, AJ, SK, JM, ASP, DR, PdW, EWZ, HZ, ML and AIM: none. RJG: advisory board and speaker bureau for AstraZeneca, Aspen/GSK, Cipla, MSD and Novartis.

[1.] South African Childhood Asthma Working Group. Management of chronic childhood and adolescent asthma - 1994 consensus. S Afr Med J 1994; 84(12):862-866.

[2.] South African Childhood Asthma Working Group. Guideline for the management of chronic asthma in children - 2000 update. S Afr Med J 2000; 90(5):524-539.

[3.] South African Childhood Asthma Working Group. Management of chronic childhood and adolescent asthma - 2009 update. S Afr Med J 2009; 9(12):898-912.

[4.] Global Initiative for Asthma. (accessed 22 January 2017).

[5.] Hossny E, Rosario N, Lee BW, et al. The use of inhaled corticosteroids in pediatric asthma: Update. World Allergy Organ J 2016; 9:26.

[6.] Pedersen S. Inhalers and nebulizers: Which to choose and why. Respir Med 1996; 90(2):69-77. https://

[7.] Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; (2):CD000052. CD000052.pub2

[8.] Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: A systematic review with meta-analysis. J Pediatr 2004; 145(2):172-177. jpeds.2004.04.007

[9.] Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013; (9):CD000052. CD000052.pub3

[10.] Fink JB. Aerosol device selection: Evidence to practice. Respir Care 2000; 45(7):874-885.

[11.] Dhand R. Aerosol therapy for asthma. Curr Opin Pulm Med 2000; 6(1):59-70. https://doi. org/10..1097/00063198-200001000-00012

[12.] Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005; 39(5):447-451.

[13.] Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2005; (2):CD002310.

[14.] Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; (1):CD002738. CD002738.pub2

[15.] Calpin C, Macarthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: A systemic review of the literature. J Allergy Clin Immunol 1997; 100(4):452-457.

[16.] O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8):13921397.

[17.] Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet 2003; 361(9363):1071-1076. S0140-6736(03)12891-7

[18.] Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343(5):332-336. NEJM200008033430504

[19.] Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ 2003; 326(7390):621. bmj.326.7390.621

[20.] Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3):e48. https://doi. org/10.1542/peds.108.3.e48

[21.] Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20(10):1549-1558. https://doi. org/10.1185/030079904X3348

[22.] Valovirta E, Boza ML, Robertson CF, et al Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol 2011; 106(6):518-526. https://doi. org/10.1016/j.anai.2011.01.017

[23.] Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31(4):616-624. https://doi. org/10.1046/j.1365-2222.2001.01088.x

[24.] Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting [beta.sub.2]-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009; (4):CD005307.

[25.] Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF, and the Dutch Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 1998; 158(1):213-219.

[26.] Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010; (4):CD005533.

[27.] Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; (12):CD009019. CD009019.pub2

[28.] Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/ formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12:38.

[29.] Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; (4):CD007313.

[30.] Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: A double-blind, randomised controlled trial. Lancet Respir Med 2013; 1(1):23-31.

[31.] Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial. Lancet Respir Med 2013; 1(1):32-42.

[32.] Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337(20):1412-1418.

[33.] Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: A systematic review with meta-analysis. Chest 2015; 147(2):388-396.

[34.] Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319(7202):87-90.

[35.] Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58(3):211-216.

[36.] Tamaoki J, Kondo M, Sakai N, et al., and the Tokyo Joshi-Idai Asthma Research Group. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155(4):1235-1240.

[37.] Virchow JC, Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162(2):578-585.

[38.] Sorkness CA, Lemanske RF, Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119(1):64-72.

[39.] Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: An evidence-based approach. Med J Aust 2003; 178(5):223-225.

[40.] Brozek JL, Kraft M, Krishnan JA, et al Long-acting [beta.sub.2]-agonist step-off in patients with controlled asthma. Arch Intern Med 2012; 172(18):1365-1375.

[41.] Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. Allergy 2014; 69(4):510-516.

Accepted 7 May 2018.

Appendix A. The SA Childhood Asthma Working Group (SACAWG)

Epidemiology: H Zar (leader), Western Cape; C Gray, Western Cape.

Diagnosis of asthma: R Masekela (leader), KwaZulu-Natal; S M Risenga, Limpopo; O P Kitchin, Gauteng; P Goussard, Western Cape.

Assessment of asthma control: R J Green (leader), Gauteng; A van Niekerk, Gauteng; D White, Gauteng; G Davis, Gauteng.

Pharmacotherapy: F E Kritzinger (leader), Western Cape; A Jeevanathrum, Gauteng; P de Waal, Free State; S Kling, Western Cape; A Vanker, Western Cape; T C Gray, Western Cape; J Morrison, Western Cape; A Puterman, Western Cape; E Zollner, Western Cape; D Rhode, Western Cape.

Pharmacotherapy--other therapies: A I Manjra (leader), KwaZulu-Natal; P M Jeena, KwaZulu-Natal; V Naidoo, KwaZulu-Natal;

M Annamalai, KwaZulu-Natal; A van Niekerk, Gauteng.

Self-management plans: M Levin (leader), Western Cape; S Emanuel, Western Cape; D Hawarden, Western Cape; H Katz, Gauteng.

Appendix B. Level of evidence

IA Evidence from meta-analysis and randomised controlled trials IB Evidence from at least one randomised controlled trial IIA Evidence from at least one controlled trial without randomisation IIB Evidence from at least one or other quasi-experimental study III Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-controlled studies

IV Evidence from expert committee reports, opinions or clinical experience of respected authorities
Appendix B. Grades of Recommendation Assessment,
Development and Evaluation (GRADE)

Level or         Quality of   Definition
recommendation   evidence

A                High         High-quality research very unlikely
                              to change our confidence in the
                              estimate effect based on level I

B                Moderate     Moderate-quality evidence, where
                              future research is likely to have an
                              important impact on our confidence in
                              the estimate effect. Based on level
                              II evidence or extrapolated from
                              recommendations from level I evidence

C                Low          Low-quality evidence, where future
                              research is likely to have an
                              important impact on our confidence in
                              the estimate effect. Based on level
                              III evidence or recommendations from
                              level I and II evidence

D                Very low     Very-low-quality evidence, where the
                              estimate effect is uncertain. Based
                              on level IV evidence

R Masekela, (1) PhD; A Jeevanathrum, (2) Cert Pulmonology (SA) Paed; S Kling, (3) FCPaed (SA), MPhil (Appl Ethics); T C Gray, (3) Cert Pulmonology (SA) Paed; J Morrison, (3) Cert Pulmonology (SA) Paed; A Vanker, (4) Cert Pulmonology (SA) Paed; A S Puterman, (5) FC Paed (SA); D Rhode, (6) Cert Pulmonology (SA) Paed; E W Zollner, (3) PhD; P de Waal, (7) MMed (Paed); A I Manjra, (8) FCPaed (SA), M Clin Pharm; M Levin, (4) PhD; H Zar, (4) PhD; R J Green, (2) PhD, DSc; F E Kritzinger, (3,9) Cert Pulmonology (SA) Paed; on behalf of the South African Childhood Asthma Working Group (SACAWG)

(1) Inkosi Albert Luthuli Central Hospital and Department of Paediatrics and Child Health, School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

(2) Steve Biko Academic Hospital and Department of Paediatrics and Child Health, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa

(3) Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

(4) Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, and Medical Research Council Unit on Child and Adolescent Health, Faculty of Health Sciences, University of Cape Town, South Africa

(5) Private practice, Life Kingsbury Hospital, Cape Town, South Africa

(6) Private practice, Melomed Private Hospital, Cape Town, South Africa

(7) Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa

(8) Private practice, Life Westville Hospital, Durban, South Africa

(9) Netcare Christiaan Barnard Memorial Hospital, Cape Town, South Africa

Corresponding author: R Masekela (
Table 1. Classification of asthma severity based on symptoms and
lung function (presenting for the first time without treatment)

Classification          Mild intermittent     Mild persistent

Symptoms                [less than or         >2/week
                          equal to] 2/week
Night-time symptoms     [less than or         >1/month
                          equal to] 1/month
PEF (predicted), %      [greater than or      [greater than
                          equal to] 80          or equal to] 80
PEFR variability, % *   <20                   20-30

Classification          Moderate persistent   Severe persistent

Symptoms                Daily                 Continual

Night-time symptoms     >1/week               Frequent

PEF (predicted), %      >60 - [less than      [less than or
                          or equal to] 80       equal to] 60
PEFR variability, % *   >30                   >30

PEF = peak expiratory flow; PEFR = peak expiratory flow rate.

* Applicable to children >5 years old.

Table 2. Preferred low-dose ICS in children <5 years old *

ICS                                       Total daily inhaled
                                          dose, [micro]g

Beclomethasone dipropionate (HFA)         100
Budesonide (pMDI and spacer) ([dagger])   200
Budesonide (nebulised) ([dagger])         500
Fluticasone propionate (HFA)              100

ICS = inhaled corticosteroid; HFA = hydrofluoroalkane; pMDI =
pressurised metered-dose inhaler.

* Adapted from Global Initiative for Asthma. [4]

([dagger]) Most preparations are registered for twice-daily
use, except budesonide, which may be administered once daily.

Table 3. Estimated equipotent daily dosage of ICS for children 6-11
years old

Drug                  Low daily   Medium daily   High daily
                      dose,       dose,          dose,
                      [micro]g    [micro]g       [micro]g

Beclomethasone        100-200     200-400        >400
dipropionate CFC

Budesonide DPI        100-200     200-400        >400

Ciclesonide HFA *     80          80-160         >160

Fluticasone           100-200     200-500        >500
propionate HFA

Mometasone furoate    110         220 - <440     [greater than or
                                                  equal to] 440

                      Adolescents ([greater
                      than or equal to]
                      12 years old)

Beclomethasone        100-200                 >200-400    >400
dipropionate HFA

Budesonide DPI        200-400                 >400-800    >800

Ciclesonide HFA       80-160                  >160-320    >320

Fluticasone           100-250                 >250-500    >500
propionate HFA

Fluticasone furoate   --                      --          --
([double dagger])

Mometasone furoate    110-220                 >220-440    >440

CFC = chlorofluorocarbon; DPI = dry powder inhaler; HFA =

* Ciclesonide is registered for children [greater than or equal
to] 12 years old.

([dagger]) May be used at half the dose of budesonide equivalent.
([double dagger]) Equivalent doses

Table 4. Combination products available in South Africa *

Combination               Device               Dose, [micro]g

Fluticasone propionate/   DPI (Accuhaler)      100/50
salmeterol                                     250/50
Fluticasone propionate/   pMDI                 50/25
salmeterol                                     125/25
Budesonide/formoterol     pMDI                 80/4.5
fumarate                                       160/4.5
Budesonide/formoterol     DPI (Turbuhaler)     80/4.5
fumarate                                       160/4.5
Fluticasone furoate/      pMDI                 100/25
vilanterol ([dagger])
Mometasone furoate/       pMDI                 100/5
formoterol fumarate
Mometasone furoate/       pMDI CFC free        100/5
formoterol fumarate                            200/5

pMDI = pressurised metered-dose inhaler; DPI = dry powder inhaler;
CFC = chlorofluorocarbon.

* Adapted from Global Initiative for Asthma [4] and Hossny et al. [5]

([dagger]) Indicated only for children [greater than or equal to] 12
years old.

Table 5. Asthma treatment options for children 2-5 years of age

                             Step 1

Intermittent reliever therapy    SABA as needed

                             Step 2

Low-dose controller and          Low-dose ICS
as-needed reliever medication    Intermittent ICS (second
                                 choice if seasonal symptoms)

                             Step 3

Additional controller and        Medium-dose ICS
as-needed reliever medication    Low-dose ICS and LTRA

                             Step 4

Refer to specialist (paediatrician, paediatric allergologist or
paediatric pulmonologist)

SABA = short-acting [beta.sub.2]-agonist; ICS = inhaled
corticosteroid; LTRA = leukotriene receptor antagonist.

Table 6. Asthma treatment options for children
[greater than or equal to] 6 years old

                             Step 1

Intermittent reliever therapy   SABA as needed

                             Step 2

Low-dose controller and         Low-dose ICS
as-needed reliever medication

                             Step 3

Additional controller and       Low-dose ICS/LABA
as-needed reliever medication   combination therapy (first
                                Medium-dose ICS (second

                             Step 4

>2 controllers and as-needed    Low-dose ICS/LABA and
reliever medication             LTRA
                                Medium-dose ICS and LABA
                                Tiotropium (>12 years of age)
                                --add to step 3 drugs
                                Theophylline (>12 years of age)

                             Step 5

Refer to specialist (paediatrician, paediatric allergologist or
paediatric pulmonologist)

SABA = short-acting [beta.sub.2]-agonist; ICS = inhaled
corticosteroid; LABA = long-acting [beta.sub.2]-agonist;
LTRA = leukotriene receptor antagonist.
COPYRIGHT 2018 Health & Medical Publishing Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Masekela, R.; Jeevanathrum, A.; Kling, S.; Gray, T.C.; Morrison, J.; Vanker, A.; Puterman, A.S.; Rho
Publication:SAMJ South African Medical Journal
Article Type:Report
Date:Aug 1, 2018
Previous Article:He who refuses to obey cannot command: A guide to paediatric asthma management.
Next Article:Looking beyond the magic bullet: Novel asthma drugs or education, which works better?

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |